[{"orgOrder":0,"company":"Church & Dwight Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Dentifrice","moa":"Bacterial biofilm","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Church & Dwight Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Church & Dwight Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Church & Dwight Co \/ Undisclosed"},{"orgOrder":0,"company":"Church & Dwight Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Dentifrice","moa":"Bacterial biofilm","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Church & Dwight Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Church & Dwight Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Church & Dwight Co \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Vantage Data Designs | Syneos Health | Agility Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Gel","sponsorNew":"Armata Pharmaceuticals \/ Vantage Data Designs | Syneos Health | Agility Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Vantage Data Designs | Syneos Health | Agility Clinical"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Vantage Data Designs | E Squared Trials and Registries | Agility Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Strip","sponsorNew":"Armata Pharmaceuticals \/ Vantage Data Designs | E Squared Trials and Registries | Agility Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Vantage Data Designs | E Squared Trials and Registries | Agility Clinical"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"C16G2","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dexcel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Dexcel Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexcel Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dexcel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Universitat Internacional de Catalunya","sponsor":"Dentaid","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Universitat Internacional de Catalunya","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitat Internacional de Catalunya \/ Dentaid","highestDevelopmentStatusID":"8","companyTruncated":"Universitat Internacional de Catalunya \/ Dentaid"},{"orgOrder":0,"company":"Contipro Pharma a.s","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Contipro Pharma a.s","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Contipro Pharma a.s \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Contipro Pharma a.s \/ Undisclosed"},{"orgOrder":0,"company":"Iroko Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Iroko Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iroko Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Iroko Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PerioC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"PerioC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Gel","sponsorNew":"PerioC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PerioC \/ Undisclosed"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fluoride","moa":"Enamel","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SWITZERLAND","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Taurolidine","moa":"Cell wall","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geistlich Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Geistlich Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Geistlich Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SWITZERLAND","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Taurolidine","moa":"Cell wall","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Geistlich Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geistlich Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Geistlich Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Universidad de los Andes, Chile","sponsor":"Corporaci\u00f3n de Fomento de la Producci\u00f3n, Chile","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CHILE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Universidad de los Andes, Chile","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad de los Andes, Chile \/ Corporaci\u00f3n de Fomento de la Producci\u00f3n, Chile","highestDevelopmentStatusID":"8","companyTruncated":"Universidad de los Andes, Chile \/ Corporaci\u00f3n de Fomento de la Producci\u00f3n, Chile"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Fluoride","moa":"Hydroxyapatite","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"PROCTER AND GAMBLE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sodium Fluoride","moa":"Hydroxyapatite","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"PROCTER AND GAMBLE","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROCTER AND GAMBLE \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PROCTER AND GAMBLE \/ Undisclosed"},{"orgOrder":0,"company":"University of Padova, School of Dental Medicine","sponsor":"Geistlich Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deproteinized Bovine Bone","moa":"Hydroxylapatite","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"University of Padova, School of Dental Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Padova, School of Dental Medicine \/ Geistlich Pharma","highestDevelopmentStatusID":"8","companyTruncated":"University of Padova, School of Dental Medicine \/ Geistlich Pharma"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Integra Medical Inc. | University of Toronto | University of Western Ontario, Canada | Ontario Centres of Excellence","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CANADA","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Integra Medical Inc. | University of Toronto | University of Western Ontario, Canada | Ontario Centres of Excellence","highestDevelopmentStatusID":"8","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Integra Medical Inc. | University of Toronto | University of Western Ontario, Canada | Ontario Centres of Excellence"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Silver Diamine Fluoride","moa":"Immune","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ University of Washington"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Silver Diamine Fluoride","moa":"Immune","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ University of California, San Francisco"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Silver Diamine Fluoride","moa":"Immune","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ University of Washington"},{"orgOrder":0,"company":"Concordia Dent Srl","sponsor":"Carol Davila University of Medicine and Pharmacy | Romanian National Authority for Scientific Research and Innovation | University Politechnica of Bucharest | TURKEY MEDISEN Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Concordia Dent Srl","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Concordia Dent Srl \/ Carol Davila University of Medicine and Pharmacy | Romanian National Authority for Scientific Research and Innovation | University Politechnica of Bucharest | TURKEY MEDISEN Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Concordia Dent Srl \/ Carol Davila University of Medicine and Pharmacy | Romanian National Authority for Scientific Research and Innovation | University Politechnica of Bucharest | TURKEY MEDISEN Ltd"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Pharma Power Biotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"Radion-Pdt","moa":"Photosensitiser","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Pharma Power Biotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharma Power Biotec \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharma Power Biotec \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Indiana University","sponsor":"Water Pik, Inc. | Delta Dental Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Powder","sponsorNew":"Indiana University \/ Water Pik, Inc. | Delta Dental Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Indiana University \/ Water Pik, Inc. | Delta Dental Foundation"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"APD515","moa":"Salivary secretion","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PF-05089771","moa":"Sodium channel protein type IX alpha subunit","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PF-04531083","moa":"Sodium channel protein type X alpha subunit","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AAV2-hAQP1","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MeiraGTx \/ Undisclosed"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AAV2-hAQP1","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MeiraGTx \/ Undisclosed"},{"orgOrder":0,"company":"AngioLab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ALH-L1005","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"AngioLab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AngioLab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AngioLab \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Calcium Sodium Phosphosilicate","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"BioSci Research","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Calcium Sodium Phosphosilicate","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ BioSci Research","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ BioSci Research"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Calcium Sodium Phosphosilicate","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Colgate Maximum Cavity Protection Plus Sugar Acid Neutralizer","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"Biomedical Development","sponsor":"National Heart, Lung, and Blood Institute | University of Texas System","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Iocide","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Biomedical Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomedical Development \/ National Heart, Lung, and Blood Institute | University of Texas System","highestDevelopmentStatusID":"8","companyTruncated":"Biomedical Development \/ National Heart, Lung, and Blood Institute | University of Texas System"},{"orgOrder":0,"company":"Biomedical Development","sponsor":"National Heart, Lung, and Blood Institute | University of Kentucky","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Iocide","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Biomedical Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomedical Development \/ National Heart, Lung, and Blood Institute | University of Kentucky","highestDevelopmentStatusID":"8","companyTruncated":"Biomedical Development \/ National Heart, Lung, and Blood Institute | University of Kentucky"},{"orgOrder":0,"company":"HysensBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ Undisclosed"},{"orgOrder":0,"company":"HysensBio","sponsor":"The Forsyth Institute","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ The Forsyth Institute","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ The Forsyth Institute"},{"orgOrder":0,"company":"HysensBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ Undisclosed"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Meridol","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"Sangi","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nano-HAP","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"University of Texas Health Science Center at San Antonio \/ Sangi","highestDevelopmentStatusID":"8","companyTruncated":"University of Texas Health Science Center at San Antonio \/ Sangi"},{"orgOrder":0,"company":"NanoSHIFT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NTC-510","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"NanoSHIFT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NanoSHIFT \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NanoSHIFT \/ Undisclosed"},{"orgOrder":0,"company":"SCHULKE & MAYR G.M.B.H.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Octenidine Hydrochloride","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"SCHULKE & MAYR G.M.B.H.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SCHULKE & MAYR G.M.B.H. \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Oxalic Acid","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Advantage Dental Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Dental Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Dental Services \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Dental Services \/ Undisclosed"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ University of Washington"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ Undisclosed"},{"orgOrder":0,"company":"Arcadia Consumer Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Arcadia Consumer Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcadia Consumer Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcadia Consumer Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"YH14642","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"YH23537","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"McNeil Consumer Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"McNeil Consumer Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McNeil Consumer Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"McNeil Consumer Health \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Johnson & Johnson"},{"orgOrder":0,"company":"Nevakar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nevakar \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nevakar \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Potassium Nitrate","moa":"Voltage-gated inwardly rectifying potassium channel KCNH2","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Potassium Nitrate","moa":"Voltage-gated inwardly rectifying potassium channel KCNH2","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Potassium Nitrate","moa":"Voltage-gated inwardly rectifying potassium channel KCNH2","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Potassium Nitrate","moa":"Voltage-gated inwardly rectifying potassium channel KCNH2","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Strip","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Government Dental College and Research Institute, Bangalore","sponsor":"Himalaya Drug Company Ltd. India","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Government Dental College and Research Institute, Bangalore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Government Dental College and Research Institute, Bangalore \/ Himalaya Drug Company Ltd. India","highestDevelopmentStatusID":"8","companyTruncated":"Government Dental College and Research Institute, Bangalore \/ Himalaya Drug Company Ltd. India"},{"orgOrder":0,"company":"Dubai Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.A.E","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Dubai Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Dubai Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dubai Health \/ Undisclosed"},{"orgOrder":0,"company":"HysensBio","sponsor":"Byoung-Moo Seo","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KH001","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"HysensBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HysensBio \/ Byoung-Moo Seo","highestDevelopmentStatusID":"8","companyTruncated":"HysensBio \/ Byoung-Moo Seo"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
Hydroxyapatite is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Molar Incisor Hypomineralisation.
Details :
Sodium fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gingivitis.
Details :
KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dental Caries.
Details :
KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dentin Sensitivity.
Details :
KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dentin Sensitivity.
Details :
Silver Diamine Fluoride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dental Caries.
Reset All
